Results 251 to 260 of about 1,989,151 (330)

Spatial Profiling Reveals Distinct Molecular and Immune Evolution of Mouse Lung Adenocarcinoma Precancers with or Without Carcinogen Exposure

Advanced Science, EarlyView.
Tumor evolution in lung adenocarcinoma is shaped by genetic alterations and spatial immune dynamics. By integrating whole‐exome sequencing, imaging mass cytometry, and spatial transcriptomics across two mouse models, this study reveals how mutational burden, immune infiltration, and cell–state interactions evolve during early and late carcinogenesis ...
Bo Zhu, Muhammad Aminu, Pingjun Chen, Jian‐Rong Li, Chuanpeng Dong, Chenyang Li, Yanhua Tian, Shao‐Wei Lu, Hong Chen, Chenxi Ma, Xin Hu, Jie Ye, Andrew Y. Liu, Beibei Huang, Frank R. Rojas, Parra Cuentas. Edwin Roger, Ou Shi, Monique B. Nilsson, Alissa Poteete, Khaja B. Khan, Wei Lu, Luisa M. Solis Soto, Junya Fujimoto, Cara Haymaker, Ignacio I. Wistuba, Zhubo Wei, Linghua Wang, Don L. Gibbons, Ken Chen, Alexandre Reuben, Jason M. Schenkel, John V. Heymach, Chao Cheng, Jia Wu, Jianjun Zhang   +34 more
wiley   +1 more source

Expression of TIM-3 and Gal-9 Immune Checkpoints in Chronic Lymphocytic Leukemia: The Potential Role of Interleukin-27. [PDF]

Curr Issues Mol Biol
Wędrowska E, Wandtke T, Ulaszewski B, Cichocka E, Dębski R, Kopiński P, Styczyński J, Przybylski G.   +7 more
europepmc   +1 more source

PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1‐KDM5C‐IL6 Axis in ccRCC

Advanced Science, EarlyView.
PBRM1 ranks as the second most commonly mutated gene in ccRCC. This study reveals that PBRM1 loss promotes an immunosuppressive microenvironment by elevating M2 TAMs via the KDM5C–IL‐6 axis. These M2 TAMs, along with CAFs, form a barrier that excludes CD8+ T cells. Targeting IL‐6 synergizes with anti‐PD1 therapy, offering a promising strategy for PBRM1‐
Wenjiao Xia, Hongru Wang, Yu Dong, Zitong Yang, Yiyang Zhou, Zhinan Xia, Qinchen Li, Liangliang Ren, Yichun Zheng, Junliang Yan, Dongmei Ma, Zhi Chen, Xingang Cui, Guixin Zhu, Cheng Zhang   +14 more
wiley   +1 more source

Assessment of the PD-1/PD-L1/PD-L2 Immune Checkpoints Pathway in Endometrial Cancer and Its Clinical Significance. [PDF]

Cancers (Basel)
Włodarczyk-Ciekańska K, Kwiatkowska-Makuch A, Pawłowska-Łachut A, Skiba W, Suszczyk D, Kotarski J, Pieniądz-Feculak P, Pańczyszyn A, Ignatowicz A, Tarkowski R, Wertel I.   +10 more
europepmc   +1 more source

Stress‐Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer

Advanced Science, EarlyView.
Single‐cell sequencing reveals stress‐programmed immune states driving TNFα–TNFR2–mediated Treg activation and therapy resistance in breast cancer, while targeting this axis restores antitumor immunity. ABSTRACT The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer.
Zhibo Shao, Xuliren Wang, Han Zhu, Ling Yao, Qi Zhang, Zihan Zhai, Xinyi Lv, Xinyuan Xia, Yi Zhang, Xinya Lu, Xinyi Quan, Jiawen Yang, Xinwei Li, Jieyi Dong, Zhi‐ming Shao, Ruoxi Wang, Bingqiu Xiu, Jiong Wu, Sheng Chen   +18 more
wiley   +1 more source

New horizons in B-cell lymphoma immunotherapy: From immune checkpoints to precision medicine. [PDF]

Neoplasia
Zheng R, Li Y, Shi K, Pan Y, Liu K, Song J, Li L.   +6 more
europepmc   +1 more source

Host‐Directed Antiviral Activity of SB2960 Through Selective Induction and Remodeling of Stress Granules

Advanced Science, EarlyView.
Amid the ongoing threat of emerging viral pathogens, host‐directed antivirals offer a strategy to overcome viral mutation and drug resistance. SB2960, a small‐molecule inducer of stress granules (SGs), exhibits potent broad‐spectrum antiviral activity with minimal cytotoxicity.
Wan Gi Byun, Sumin Son, JinAh Lee, Minha Lee, Meehyun Ko, Songrui Zhao, Ju Hee Kim, Kannan Vaithegi, Ji Hoon Kwon, Jung Ho Lee, Sangeun Jeon, Dawon Yi, Peng Zou, Seungtaek Kim, Seung Bum Park   +14 more
wiley   +1 more source

The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy. [PDF]

J Exp Clin Cancer Res
Hussein OJ, Rayan M, Matarid TR, Elkhalifa D, Abunada HH, Therachiyil L, Khalil A, Uddin S, Maccalli C, Korashy HM.   +9 more
europepmc   +1 more source

TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy

Advanced Science, EarlyView.
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng, Jiaxing Huang, Shengnan Lv, Jian Zhang, Liangliang Zhang, Huan Liu, Yan Liu, Zhen‐An Qiao, Feng Wei, Bao‐Lian Su   +9 more
wiley   +1 more source

A dual compartment peripheral blood signature of soluble and membrane-bound immune checkpoints predicts outcome in lymphoma patients. [PDF]

Oncoimmunology
Gorgulho J, Trenkner T, Kinkel E, Fritzsche B, Kachel P, Peine S, Matschl U, Altfeld M, Huber S, Lohse AW, Alsdorf W, Bokemeyer C, Hoelzemer A, Beltran WG, von Felden J.   +14 more
europepmc   +1 more source